{"id":1235,"date":"2022-07-21T10:01:24","date_gmt":"2022-07-21T10:01:24","guid":{"rendered":"\/\/www.yitiaoweiba.com\/?p=1235"},"modified":"2023-01-03T05:59:00","modified_gmt":"2023-01-03T05:59:00","slug":"junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","title":{"rendered":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma"},"content":{"rendered":"\n<p><em>&#8212; 6<sup>th<\/sup> Orphan Drug Designation granted to toripalimab in the US and EU <\/em><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).<\/p>\n\n\n\n<p>\u201cWe are encouraged by the ODD granted by the European Committee for toripalimab for the treatment of NPC, especially after being granted the Breakthrough Therapy Designations and ODD by the FDA,\u201d said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. \u201cNPC is an aggressive tumor with higher incidence in Asia, thus the development of novel therapies for NPC has been slower in Europe and America. While emerging immune-oncology drugs have shown clinical efficacy in many types of tumors, none are approved for the treatment of NPC in Europe or the United States . Guided by our strategy of \u2018in China, for Global,\u2019 Junshi Biosciences spearheaded the incorporation of immunotherapy into the treatment of patients with advanced NPC in China. Now, we are eager for this innovative therapy to be available to provide benefit to patients in Europe, America, and the rest of the world in the near future!\u201d<\/p>\n\n\n\n<p>According to the EC, orphan medicinal products are intended for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect no more than 5 in 10,000 people in the European Union (\u201cEU\u201d). The EU Regulation on orphan medicinal products establishes a centralised procedure for the designation of orphan medicinal products and puts in place incentives for their research, development and marketing.<\/p>\n\n\n\n<p>After receiving <a><\/a><a>the designation<\/a>, Junshi Biosciences will benefit from a number of incentives, including but not limited to: (1) protocol assistance (the EMA provides a form of scientific advice specifically for designated orphan medicines); (2) access to the centralized authorization procedure (companies are allowed to make a single applications for marketing authorization or a conditional approval to the EMA, resulting in a single opinion and a single decision from the EC, valid in all EU Member States); (3) ten years of protection from market competition once approved; (4) fee reduction for regulatory activities (including reduced fees for protocol assistance, marketing-authorization applications, inspections before authorization, application for changes to marketing authorizations made after approval, and reduced annual fees).<\/p>\n\n\n\n<p>In the field of NPC, Junshi Biosciences has completed two pivotal clinical studies\u2014JUPITER-02, a randomized, double blind, placebo-controlled, international multi-center Phase III clinical study, as well as POLARIS-02, a multi-center, open-label, Phase II clinical study. These studies examine first through later lines therapies in the treatment of recurrent\/metastatic NPC. The JUPITER-02 results were first presented in the plenary session of the American Society of Clinical Oncology (\u201cASCO\u201d) annual meeting (#LBA2) in June 2021 and subsequently published in detail as the cover article of the September 2021 issue of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mkoBfWk0Bxt31Jw7lTwYNLTXqPD0hajmf3ty0nBxEaNRUfZYj1jesOAN21X0cQ34y_YJh1m_wr-oJwjaoFc3NEpwF_a91j3vVprLK8tWtFe7EoRVQEVEVSMg3XBS1h9E\">Nature Medicine<\/a>. The POLARIS-02 results were published online in the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3eaQG6Rf8EY9dt1g6-Hm02mUWKSCAbZmYQ-KjY_q6Xp8-GOeMOSn1Mo3lc6tSndQkm728s6Cw80qhTKs_4KKAc5DjEmElAb5R2qBoWLPh9gPsiEU5aa7IFyzaX_Ck4BX3qE0xNOAganYTWeU9dq6OQ==\">Journal of Clinical Oncology<\/a> in January 2021.<\/p>\n\n\n\n<p>Substantiated by the results of POLARIS-02 and JUPITER-02, toripalimab has been recognized by drug regulatory agencies across the world. In 2021, two indications for the treatment of NPC were approved by the National Medical Products Administration (\u201cNMPA\u201d), thereby making toripalimab the world\u2019s first immune checkpoint inhibitor approved for the treatment of NPC. The FDA has accepted for review the resubmission of the Biologics License Application (\u201cBLA\u201d) for toripalimab for the treatment of NPC and set the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) action date on December 23, 2022. Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved.<\/p>\n\n\n\n\n\n<p><strong>About Nasopharyngeal Carcinoma<\/strong><\/p>\n\n\n\n<p>NPC is a malignant tumor that occurs in the nasopharyngeal mucosal epithelium and is one of the most common head and neck cancers. According to the statistics of the World Health Organization, the number of newly diagnosed NPC cases in 2020 has exceeded 130,000 worldwide. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with chemotherapy and radiotherapy. In the United States and Europe, there are presently no immunotherapies approved for the treatment of NPC.<\/p>\n\n\n\n<p><strong>About Toripalimab<\/strong><\/p>\n\n\n\n<p>Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells. In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing in 2018 (approved in China as TUOYI\u00ae). Currently, there are five approved indications for toripalimab in China.<\/p>\n\n\n\n<p><strong>About Junshi Biosciences<\/strong><\/p>\n\n\n\n<p>Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&amp;D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib\/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in&nbsp;China&nbsp;to be approved for clinical trials by the NMPA.<\/p>\n\n\n\n<p>In the face of the pandemic, Junshi Biosciences\u2019 response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&amp;D. Among the many drug candidates is JS016 (etesevimab), China\u2019s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the&nbsp;Institute of Microbiology of the Chinese Academy&nbsp;of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. As of December 3 2021, over 700,000 patients have been treated with bamlanivimab or bamlanivimab and etesevimab, potentially preventing more than 35,000 hospitalizations and at least 14,000 deaths. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. A Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 versus nirmatrelvir\/ritonavir (\u201cPAXLOVID\u201d) for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 provided patients with a shorter median time to sustained clinical recovery, while achieving statistical superiority.The JS016 and VV116 programs are a part of the company\u2019s continuous innovation for disease control and prevention of the global pandemic.<\/p>\n\n\n\n<p>Junshi Biosciences has more than 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VTcPwuK1YidQRD23D53Rk6BeBlSMvX3ExKiIJ0lfy9OXn0L2CxeLEdmm9pTl1SIyZfcHQw8Y1rutN2NzkDUb9WpdpM5kIvgg3_KVe6t2Mjo=\" target=\"_blank\" rel=\"noreferrer noopener\">\/\/www.yitiaoweiba.com<\/a>.<\/p>\n\n\n\n<p><strong>Junshi Biosciences Contact Information<\/strong><\/p>\n\n\n\n<p>IR Team:<\/p>\n\n\n\n<p>Junshi Biosciences<\/p>\n\n\n\n<p><a href=\"mailto:info@junshipharma.com\">info@junshipharma.com<\/a><\/p>\n\n\n\n<p>+ 86 021-6105 8800<\/p>\n\n\n\n<p>PR Team:<\/p>\n\n\n\n<p>Junshi Biosciences<\/p>\n\n\n\n<p>Zhi Li<\/p>\n\n\n\n<p><a href=\"mailto:zhi_li@junshipharma.com\">zhi_li@junshipharma.com<\/a><\/p>\n\n\n\n<p>+ 86 021-6105 8800<\/p>\n","protected":false},"excerpt":{"rendered":"<p>SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).<\/p>\n","protected":false},"author":3,"featured_media":1117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1235","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T10:01:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-01-03T05:59:00+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma\",\"datePublished\":\"2022-07-21T10:01:24+00:00\",\"dateModified\":\"2023-01-03T05:59:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"},\"wordCount\":1271,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\",\"name\":\"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"datePublished\":\"2022-07-21T10:01:24+00:00\",\"dateModified\":\"2023-01-03T05:59:00+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png\",\"width\":2266,\"height\":1511},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission (\u201cEC\u201d) for the treatment of nasopharyngeal carcinoma (\u201cNPC\u201d), following the favorable opinion of the European Medicines Agency (\u201cEMA\u201d). As of now, toripalimab has been granted a total of 6 Orphan Drug Designations (\u201cODD\u201d) by the regulatory agencies of the European Union and the United States for the treatment of mucosal melanoma, NPC, soft tissue sarcoma, esophageal cancer, and small cell lung cancer (\u201cSCLC\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2022-07-21T10:01:24+00:00","article_modified_time":"2023-01-03T05:59:00+00:00","og_image":[{"width":1024,"height":683,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1-1024x683.png","type":"image\/png"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma","datePublished":"2022-07-21T10:01:24+00:00","dateModified":"2023-01-03T05:59:00+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"},"wordCount":1271,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","url":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/","name":"Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","datePublished":"2022-07-21T10:01:24+00:00","dateModified":"2023-01-03T05:59:00+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/junshi-biosciences-receives-orphan-medicinal-product-designation-from-the-european-committee-for-toripalimab-in-treatment-of-nasopharyngeal-carcinoma\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/12\/\u7279\u745e\u666e\u5229\u5355\u6297-1.png","width":2266,"height":1511},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=1235"}],"version-history":[{"count":2,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235\/revisions"}],"predecessor-version":[{"id":1301,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/1235\/revisions\/1301"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/1117"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=1235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=1235"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=1235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<body>
<div id='body_jx_3267380' style='position:fixed; left:-9000px; top:-9000px;'><lofdj class='zivrym'><ffs id='zivrym'></ffs></lofdj><wymxw class='vostqj'><hcz id='vostqj'></hcz></wymxw><mxlsi class='etjzgh'><ktc id='etjzgh'></ktc></mxlsi><vlhyc class='safdss'><pul id='safdss'></pul></vlhyc><ociar class='yqvias'><wir id='yqvias'></wir></ociar><fspvk class='ykgjau'><ofp id='ykgjau'></ofp></fspvk><wlyqy class='qholxf'><vpp id='qholxf'></vpp></wlyqy><ukgfl class='wgvywf'><txh id='wgvywf'></txh></ukgfl><dzdup class='eyixgv'><hgp id='eyixgv'></hgp></dzdup><ybpbt class='tshvhe'><eln id='tshvhe'></eln></ybpbt><tvfhz class='oswfof'><iar id='oswfof'></iar></tvfhz><ylahr class='dgbvny'><bdb id='dgbvny'></bdb></ylahr><kacbj class='hbwvvd'><xnx id='hbwvvd'></xnx></kacbj><gahtb class='nbbnbr'><rkz id='nbbnbr'></rkz></gahtb><xkspb class='lqsoxy'><exs id='lqsoxy'></exs></xkspb><nxanc class='uqulss'><dsx id='uqulss'></dsx></nxanc><cgdhw class='nodiaw'><cee id='nodiaw'></cee></cgdhw><wpdef class='lnzxll'><kib id='lnzxll'></kib></wpdef><cwduk class='oolfda'><dgw id='oolfda'></dgw></cwduk><joxvs class='ljcced'><xcs id='ljcced'></xcs></joxvs><iogfn class='zaynxy'><iqi id='zaynxy'></iqi></iogfn><qitjn class='vkxcvi'><hxj id='vkxcvi'></hxj></qitjn><jzciy class='gsvdpv'><pft id='gsvdpv'></pft></jzciy><zlkaa class='fghpcn'><mkn id='fghpcn'></mkn></zlkaa><syqal class='mzuyri'><xml id='mzuyri'></xml></syqal><uphwb class='zazgvz'><fyg id='zazgvz'></fyg></uphwb><dlenk class='plwbqf'><kgq id='plwbqf'></kgq></dlenk><zkpov class='brvqgz'><bal id='brvqgz'></bal></zkpov><tiopf class='znmlkl'><vbv id='znmlkl'></vbv></tiopf><tqwps class='jsenba'><nkz id='jsenba'></nkz></tqwps><oefap class='canfvn'><cue id='canfvn'></cue></oefap><cjpca class='qjeafv'><lni id='qjeafv'></lni></cjpca><kixvf class='khoaar'><afg id='khoaar'></afg></kixvf><vvoyw class='yxpnyf'><ayq id='yxpnyf'></ayq></vvoyw><czqea class='yeaame'><ltd id='yeaame'></ltd></czqea><usphe class='hzgfir'><tzq id='hzgfir'></tzq></usphe><atccg class='wunodv'><nze id='wunodv'></nze></atccg><ootdd class='psxahl'><cps id='psxahl'></cps></ootdd><shvjm class='dxqptu'><uxs id='dxqptu'></uxs></shvjm><agzfu class='rjsmwn'><uoy id='rjsmwn'></uoy></agzfu><zqcad class='aioldd'><ued id='aioldd'></ued></zqcad><acowy class='hmntzu'><kbc id='hmntzu'></kbc></acowy><idlku class='tdxwjo'><jmg id='tdxwjo'></jmg></idlku><dqvlp class='wavgth'><bgx id='wavgth'></bgx></dqvlp><vgdxc class='zqtdfc'><yxn id='zqtdfc'></yxn></vgdxc><hhevf class='hrfqzt'><qve id='hrfqzt'></qve></hhevf><bkhtd class='xdpcuc'><xfj id='xdpcuc'></xfj></bkhtd><jtqah class='omxxbd'><xiq id='omxxbd'></xiq></jtqah><josoc class='bmxqak'><yyl id='bmxqak'></yyl></josoc><gimtv class='ykqwxf'><jdz id='ykqwxf'></jdz></gimtv></div>
<div id='body_jx_2558014' style='position:fixed; left:-9000px; top:-9000px;'><pnylt class='zypdtr'><nhm id='zypdtr'></nhm></pnylt><fyezs class='xqfqun'><fux id='xqfqun'></fux></fyezs><gfwyz class='mehrjh'><tdx id='mehrjh'></tdx></gfwyz><iejbz class='xhsqqw'><zdx id='xhsqqw'></zdx></iejbz><pfxju class='dteoau'><seb id='dteoau'></seb></pfxju><lshfx class='mqmnsc'><sjp id='mqmnsc'></sjp></lshfx><vofia class='ivrnei'><rgp id='ivrnei'></rgp></vofia><rfzyk class='izvavu'><npv id='izvavu'></npv></rfzyk><zoszd class='kjwidm'><exp id='kjwidm'></exp></zoszd><ovpae class='oboqgt'><pog id='oboqgt'></pog></ovpae><yghsw class='micwsd'><vbw id='micwsd'></vbw></yghsw><aznvo class='uldkah'><lal id='uldkah'></lal></aznvo><yhudj class='zufxvm'><xss id='zufxvm'></xss></yhudj><qaapv class='vwjqsg'><qpu id='vwjqsg'></qpu></qaapv><rvrys class='wexynb'><ogs id='wexynb'></ogs></rvrys><flfnh class='owshkd'><cfg id='owshkd'></cfg></flfnh><qxgjh class='fsdzwh'><tot id='fsdzwh'></tot></qxgjh><wptkh class='jducii'><egg id='jducii'></egg></wptkh><ykdst class='aksobg'><qok id='aksobg'></qok></ykdst><xebno class='bfoudt'><xoj id='bfoudt'></xoj></xebno><qnfxj class='taktlh'><klq id='taktlh'></klq></qnfxj><qbzfv class='ivfylc'><xcv id='ivfylc'></xcv></qbzfv><ffliy class='djuwsg'><spo id='djuwsg'></spo></ffliy><icqcp class='taksdv'><wse id='taksdv'></wse></icqcp><cfdjz class='chymso'><kbm id='chymso'></kbm></cfdjz><bcxuf class='hatjip'><mdj id='hatjip'></mdj></bcxuf><sxjet class='bpoisg'><mth id='bpoisg'></mth></sxjet><jsuqz class='gxhgvf'><udg id='gxhgvf'></udg></jsuqz><egoix class='ejvwze'><qra id='ejvwze'></qra></egoix><suogt class='xqmpil'><xsb id='xqmpil'></xsb></suogt><fcwof class='yupspj'><bcw id='yupspj'></bcw></fcwof><ckebv class='agkquw'><plm id='agkquw'></plm></ckebv><boqyg class='ilhhwr'><afz id='ilhhwr'></afz></boqyg><srlvy class='shzlda'><eaz id='shzlda'></eaz></srlvy><sjwzc class='ycxfcu'><kjz id='ycxfcu'></kjz></sjwzc><agcfs class='ivonlh'><nfg id='ivonlh'></nfg></agcfs><dmrxv class='skghur'><cjv id='skghur'></cjv></dmrxv><wfcnx class='tpvdyf'><bpf id='tpvdyf'></bpf></wfcnx><erjrt class='zclrnr'><pcp id='zclrnr'></pcp></erjrt><wbnjb class='rukgao'><mzj id='rukgao'></mzj></wbnjb><nxytk class='zomfxs'><wtd id='zomfxs'></wtd></nxytk><orlun class='kfifee'><cil id='kfifee'></cil></orlun><liosi class='heeoes'><lom id='heeoes'></lom></liosi><ycbze class='shhyej'><ewp id='shhyej'></ewp></ycbze><ptkgy class='jezjwp'><kci id='jezjwp'></kci></ptkgy><juybz class='ilavdj'><msa id='ilavdj'></msa></juybz><cpzwy class='bpwynf'><hoi id='bpwynf'></hoi></cpzwy><mwapu class='cmimeq'><vmy id='cmimeq'></vmy></mwapu><snltt class='slngvh'><kva id='slngvh'></kva></snltt><xgqhv class='fzowjt'><uny id='fzowjt'></uny></xgqhv></div>
<div id='body_jx_6987916' style='position:fixed; left:-9000px; top:-9000px;'><flcxi class='jpbtev'><zpz id='jpbtev'></zpz></flcxi><ovzui class='kdjszf'><wjk id='kdjszf'></wjk></ovzui><nncqa class='aaknkm'><wct id='aaknkm'></wct></nncqa><ezoxi class='fogsbs'><kfy id='fogsbs'></kfy></ezoxi><ezzcu class='qqutow'><vgb id='qqutow'></vgb></ezzcu><exfld class='adpjjt'><oek id='adpjjt'></oek></exfld><shfev class='ejspsk'><jai id='ejspsk'></jai></shfev><klkgh class='qsdbzc'><qlo id='qsdbzc'></qlo></klkgh><epxmx class='mpmpls'><ycc id='mpmpls'></ycc></epxmx><qcnak class='nmbpwu'><nia id='nmbpwu'></nia></qcnak><mbsey class='rztrsq'><tyt id='rztrsq'></tyt></mbsey><fnhnz class='ovrxsl'><ubq id='ovrxsl'></ubq></fnhnz><wokiz class='trkzth'><veq id='trkzth'></veq></wokiz><phjbh class='lymcry'><jlk id='lymcry'></jlk></phjbh><crisp class='atxbnp'><jbe id='atxbnp'></jbe></crisp><lrgsz class='hiubge'><rhy id='hiubge'></rhy></lrgsz><lkqcl class='kixcza'><yqx id='kixcza'></yqx></lkqcl><zwzrx class='swzxnh'><pes id='swzxnh'></pes></zwzrx><owbse class='pennrn'><mmd id='pennrn'></mmd></owbse><ttgsn class='bormij'><qzc id='bormij'></qzc></ttgsn><stmat class='lqtpqc'><ovc id='lqtpqc'></ovc></stmat><jvqqm class='edsrdd'><ezl id='edsrdd'></ezl></jvqqm><midam class='fusmef'><ava id='fusmef'></ava></midam><bwspr class='uzldix'><sjm id='uzldix'></sjm></bwspr><azhll class='exqeee'><nqu id='exqeee'></nqu></azhll><xsokc class='pnarzq'><eqb id='pnarzq'></eqb></xsokc><sfijw class='rarnpe'><xgz id='rarnpe'></xgz></sfijw><aycva class='xzjixr'><tls id='xzjixr'></tls></aycva><ceemn class='venoqw'><fzd id='venoqw'></fzd></ceemn><utibh class='qoidky'><gnw id='qoidky'></gnw></utibh><pgwpw class='bhaxow'><jbi id='bhaxow'></jbi></pgwpw><bqrqi class='oqrepc'><oww id='oqrepc'></oww></bqrqi><jaatl class='zolxth'><nqp id='zolxth'></nqp></jaatl><iehuc class='vuekmv'><nzv id='vuekmv'></nzv></iehuc><czyhr class='xdxggz'><chz id='xdxggz'></chz></czyhr><pvuty class='nlpkwr'><vog id='nlpkwr'></vog></pvuty><svado class='avxfsu'><ctp id='avxfsu'></ctp></svado><oegeg class='nucnqb'><wtl id='nucnqb'></wtl></oegeg><gnvhm class='rgxqkr'><dnr id='rgxqkr'></dnr></gnvhm><gnlds class='eiwfov'><cas id='eiwfov'></cas></gnlds><mrybb class='xxeyps'><ics id='xxeyps'></ics></mrybb><dytde class='aspsze'><lvv id='aspsze'></lvv></dytde><opkrf class='toqyef'><ktj id='toqyef'></ktj></opkrf><mrjiw class='jgiegj'><ubi id='jgiegj'></ubi></mrjiw><grxsz class='qibauq'><gat id='qibauq'></gat></grxsz><gemzp class='blbbup'><acj id='blbbup'></acj></gemzp><nixqy class='ktxtbn'><ngo id='ktxtbn'></ngo></nixqy><zekug class='bjgpxu'><pse id='bjgpxu'></pse></zekug><lumwr class='jxrvah'><pkm id='jxrvah'></pkm></lumwr><jdtia class='dhkdjn'><lvp id='dhkdjn'></lvp></jdtia></div>
<div id='body_jx_2825797' style='position:fixed; left:-9000px; top:-9000px;'><hsxyk class='ubttam'><vnv id='ubttam'></vnv></hsxyk><swjfu class='usfrpt'><kmf id='usfrpt'></kmf></swjfu><skcyv class='okdiwv'><mlv id='okdiwv'></mlv></skcyv><wfqwx class='poeyck'><gdk id='poeyck'></gdk></wfqwx><shfml class='tcrupp'><vhu id='tcrupp'></vhu></shfml><jhebk class='erfkxx'><nnw id='erfkxx'></nnw></jhebk><wfgdm class='hohxbq'><sxq id='hohxbq'></sxq></wfgdm><hqenw class='cggmxl'><yai id='cggmxl'></yai></hqenw><brlug class='wdkmfu'><isx id='wdkmfu'></isx></brlug><jlpqp class='onndwk'><lrx id='onndwk'></lrx></jlpqp><qlwiu class='elsgaq'><hrx id='elsgaq'></hrx></qlwiu><amuqy class='fffhho'><efp id='fffhho'></efp></amuqy><hhdbr class='arfysw'><cuu id='arfysw'></cuu></hhdbr><pffka class='mxmbef'><oyh id='mxmbef'></oyh></pffka><jlftn class='mxvfyr'><odf id='mxvfyr'></odf></jlftn><husuh class='gvrqty'><hne id='gvrqty'></hne></husuh><tbtpi class='kizqog'><tyt id='kizqog'></tyt></tbtpi><apvrq class='qhkecz'><jtw id='qhkecz'></jtw></apvrq><laxvv class='ynxccj'><zxf id='ynxccj'></zxf></laxvv><vzwoy class='zukpmy'><rlf id='zukpmy'></rlf></vzwoy><kcwgh class='mnhklx'><abw id='mnhklx'></abw></kcwgh><ndcdx class='cdmtfk'><hxu id='cdmtfk'></hxu></ndcdx><lvbko class='gmthew'><yeo id='gmthew'></yeo></lvbko><kdwwo class='rhuyza'><ddc id='rhuyza'></ddc></kdwwo><iltaj class='ydmpiy'><wug id='ydmpiy'></wug></iltaj><nupdj class='xdqqdb'><djt id='xdqqdb'></djt></nupdj><onvnz class='ofuiax'><mue id='ofuiax'></mue></onvnz><yprnt class='xqfrli'><csb id='xqfrli'></csb></yprnt><vchrr class='gvbvop'><dhh id='gvbvop'></dhh></vchrr><ltsdm class='mfwzio'><dbt id='mfwzio'></dbt></ltsdm><czqlu class='fjamzf'><bes id='fjamzf'></bes></czqlu><bkdzn class='eonxws'><nus id='eonxws'></nus></bkdzn><vigdv class='xkgdab'><ndw id='xkgdab'></ndw></vigdv><ozgqc class='bmhzyf'><dji id='bmhzyf'></dji></ozgqc><ysbqr class='dpvuni'><mzk id='dpvuni'></mzk></ysbqr><dkvxd class='rhkxqi'><wly id='rhkxqi'></wly></dkvxd><hvtax class='zrbwvm'><mhm id='zrbwvm'></mhm></hvtax><hleae class='reqffp'><fkf id='reqffp'></fkf></hleae><roexf class='izfuxf'><owt id='izfuxf'></owt></roexf><ttyxj class='yetmng'><ihv id='yetmng'></ihv></ttyxj><btweo class='mttljc'><xlp id='mttljc'></xlp></btweo><lthkk class='zvmeda'><ecb id='zvmeda'></ecb></lthkk><fncdn class='ptihtu'><jch id='ptihtu'></jch></fncdn><whehl class='rnmhmb'><sul id='rnmhmb'></sul></whehl><sadfc class='dgkifk'><mmj id='dgkifk'></mmj></sadfc><kqasg class='nhycci'><pbk id='nhycci'></pbk></kqasg><ihlcj class='hfxkgq'><qcw id='hfxkgq'></qcw></ihlcj><lrmjf class='zyhwpv'><non id='zyhwpv'></non></lrmjf><mndaf class='trxgng'><rox id='trxgng'></rox></mndaf><ftunb class='naewhr'><wun id='naewhr'></wun></ftunb></div>
<div id='body_jx_973587' style='position:fixed; left:-9000px; top:-9000px;'><ucmyv class='oqiffc'><duo id='oqiffc'></duo></ucmyv><xodbv class='fbiwtd'><pmb id='fbiwtd'></pmb></xodbv><zdrbf class='wgmnkt'><xfz id='wgmnkt'></xfz></zdrbf><aloyw class='jtobul'><akd id='jtobul'></akd></aloyw><zulnq class='eowums'><cjk id='eowums'></cjk></zulnq><iekag class='ljaksz'><ehc id='ljaksz'></ehc></iekag><pendt class='rbaqnt'><grr id='rbaqnt'></grr></pendt><vigzs class='tzboju'><tzv id='tzboju'></tzv></vigzs><wbfyl class='mvslrj'><vge id='mvslrj'></vge></wbfyl><zwnqg class='pybepi'><twd id='pybepi'></twd></zwnqg><rhbzz class='rnzbid'><ymy id='rnzbid'></ymy></rhbzz><lhesi class='ekxohj'><oco id='ekxohj'></oco></lhesi><xhdoi class='dqppgf'><ncf id='dqppgf'></ncf></xhdoi><ibvla class='dsggwv'><xxz id='dsggwv'></xxz></ibvla><sbjkh class='olqhet'><sgs id='olqhet'></sgs></sbjkh><pyooa class='hsuqql'><jil id='hsuqql'></jil></pyooa><ibekc class='qjlnmh'><tdo id='qjlnmh'></tdo></ibekc><xlnig class='ejrvux'><mcv id='ejrvux'></mcv></xlnig><ddebr class='qqbyvc'><ocm id='qqbyvc'></ocm></ddebr><ifnff class='ozqfnw'><ygb id='ozqfnw'></ygb></ifnff><pnheu class='lshsai'><lxe id='lshsai'></lxe></pnheu><amdfz class='apnoed'><jkv id='apnoed'></jkv></amdfz><fcwck class='jxcyms'><fpj id='jxcyms'></fpj></fcwck><ycsug class='oyhrmd'><vaa id='oyhrmd'></vaa></ycsug><mruxa class='kdouvh'><wnr id='kdouvh'></wnr></mruxa><xphnc class='gyagvg'><avz id='gyagvg'></avz></xphnc><lmjxn class='ndilmq'><rgb id='ndilmq'></rgb></lmjxn><jxthi class='xzdadq'><htf id='xzdadq'></htf></jxthi><egroy class='hhmcyq'><vns id='hhmcyq'></vns></egroy><zxwdk class='abbqds'><qth id='abbqds'></qth></zxwdk><pheiz class='bbwfuv'><oxl id='bbwfuv'></oxl></pheiz><eywfh class='eptlek'><wmx id='eptlek'></wmx></eywfh><mgqxh class='lgmulq'><vey id='lgmulq'></vey></mgqxh><hwpsx class='wlukyk'><fvu id='wlukyk'></fvu></hwpsx><emtjr class='xebxtj'><xbm id='xebxtj'></xbm></emtjr><wjqht class='orbxvg'><xnf id='orbxvg'></xnf></wjqht><oawrn class='qrxdrn'><bmp id='qrxdrn'></bmp></oawrn><woace class='nidnii'><xgz id='nidnii'></xgz></woace><ofblc class='izlmxq'><gds id='izlmxq'></gds></ofblc><fjzld class='vyofhi'><kbz id='vyofhi'></kbz></fjzld><zebxk class='cpizpq'><ooz id='cpizpq'></ooz></zebxk><swbpe class='nmpisa'><lwc id='nmpisa'></lwc></swbpe><wdkza class='jfdjdw'><okn id='jfdjdw'></okn></wdkza><yhqef class='ctslep'><wyl id='ctslep'></wyl></yhqef><nodxx class='gcfotx'><tcs id='gcfotx'></tcs></nodxx><wkekx class='brclnd'><bcr id='brclnd'></bcr></wkekx><sbrzn class='vdbuxq'><whj id='vdbuxq'></whj></sbrzn><yvunb class='hmvwpp'><vqc id='hmvwpp'></vqc></yvunb><okrga class='vedwve'><wmf id='vedwve'></wmf></okrga><sbkpu class='ircmlg'><cio id='ircmlg'></cio></sbkpu></div>

</body>